Charles Schwab Investment Management Inc. Acquires 11,239 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL)

Charles Schwab Investment Management Inc. raised its position in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) by 1.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 677,215 shares of the biotechnology company’s stock after buying an additional 11,239 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Anavex Life Sciences were worth $7,273,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Berkshire Money Management Inc. purchased a new position in Anavex Life Sciences during the 4th quarter valued at approximately $107,000. Fiduciary Alliance LLC purchased a new position in Anavex Life Sciences during the 4th quarter valued at approximately $119,000. D.A. Davidson & CO. purchased a new position in Anavex Life Sciences during the 4th quarter valued at approximately $122,000. Orion Capital Management LLC grew its holdings in Anavex Life Sciences by 666.7% during the 3rd quarter. Orion Capital Management LLC now owns 11,500 shares of the biotechnology company’s stock valued at $65,000 after buying an additional 10,000 shares in the last quarter. Finally, PVG Asset Management Corp purchased a new position in Anavex Life Sciences during the 3rd quarter valued at approximately $74,000. Hedge funds and other institutional investors own 31.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on AVXL. HC Wainwright restated a “buy” rating and set a $42.00 price target on shares of Anavex Life Sciences in a report on Tuesday, February 18th. D. Boral Capital restated a “buy” rating and set a $46.00 price target on shares of Anavex Life Sciences in a report on Wednesday, February 12th.

Anavex Life Sciences Stock Performance

NASDAQ AVXL opened at $9.74 on Monday. The company has a market cap of $828.52 million, a P/E ratio of -17.71 and a beta of 0.94. The business’s 50 day moving average price is $9.10 and its 200-day moving average price is $8.18. Anavex Life Sciences Corp. has a fifty-two week low of $3.25 and a fifty-two week high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL) last released its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.03. As a group, equities analysts predict that Anavex Life Sciences Corp. will post -0.69 EPS for the current year.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.